ADVERSE O
REACTIONS O
For O
a O
comparison O
of O
toxicities O
when O
carboplatin O
or O
cisplatin O
was O
given O
in O
combination O
with O
cyclophosphamide O
, O
see O
CLINICAL O
STUDIES O
, O
Use O
with O
Cyclophosphamide O
for O
Initial O
Treatment O
of O
Ovarian B-Not_AE_Candidate
Cancer I-Not_AE_Candidate
, O
Comparative O
Toxicity O
. O

ADVERSE O
EXPERIENCES O
IN O
PATIENTS O
WITH O
OVARIAN O
CANCER O
First O
Line O
Combination O
Therapy O
[ O
note O
: O
Use O
with O
Cyclophosphamide O
for O
Initial O
Treatment O
of O
Ovarian B-Not_AE_Candidate
Cancer I-Not_AE_Candidate
: O
Data O
are O
based O
on O
the O
experience O
of O
393 O
patients O
with O
ovarian B-Not_AE_Candidate
cancer I-Not_AE_Candidate
( O
regardless O
of O
baseline O
status O
) O
who O
received O
initial O
combination O
therapy O
with O
carboplatin O
and O
cyclophosphamide O
in O
two O
randomized O
controlled O
studies O
conducted O
by O
SWOG O
and O
NCIC O
( O
see O
CLINICAL O
STUDIES O
) O
.Combination O
with O
cyclophosphamide O
as O
well O
as O
duration O
of O
treatment O
may O
be O
responsible O
for O
the O
differences O
that O
can O
be O
noted O
in O
the O
adverse O
experience O
table O
. O
] O

Percent O
Second O
Line O
Single O
Agent O
Therapy O
[ O
note O
: O
Single O
Agent O
Use O
for O
the O
Secondary O
Treatment O
of O
Ovarian O
Cancer O
: O
Data O
are O
based O
on O
the O
experience O
of O
553 O
patients O
with O
previously O
treated O
ovarian O
carcinoma O
( O
regardless O
of O
baseline O
status O
) O
who O
received O
single O
agent O
carboplatin O
. O
] O

Percent O
Bone B-NonOSE_AE
Marrow I-NonOSE_AE
Thrombocytopenia B-OSE_Labeled_AE
< O
100,000/mm3 O
66 O
62 O
< O
50,000/mm3 O
33 O
35 O
Neutropenia B-OSE_Labeled_AE
< O
2,000 O
cells/mm3 O
96 O
67 O
< O
1,000 O
cells/mm3 O
82 O
21 O
Leukopenia B-OSE_Labeled_AE
< O
4,000 O
cells/mm3 O
97 O
85 O
< O
2,000 O
cells/mm3 O
71 O
26 O
Anemia B-OSE_Labeled_AE
< O
11 O
g/dL O
90 O
90 O
< O
8g/dL O
14 O
21 O
Infections B-OSE_Labeled_AE
16 O
5 O
Bleeding B-OSE_Labeled_AE
8 O
5 O
Transfusions B-OSE_Labeled_AE
35 O
44 O
Gastrointestinal B-NonOSE_AE
Nausea B-OSE_Labeled_AE
and O
vomiting B-OSE_Labeled_AE
93 O
92 O
Vomiting B-OSE_Labeled_AE
83 O
81 O
Other O
GI B-OSE_Labeled_AE
side I-OSE_Labeled_AE
effects I-OSE_Labeled_AE
46 O
21 O
Neurologic B-NonOSE_AE
Peripheral B-OSE_Labeled_AE
neuropathies I-OSE_Labeled_AE
15 O
6 O
Ototoxicity B-OSE_Labeled_AE
12 O
1 O
Other O
sensory B-OSE_Labeled_AE
side I-OSE_Labeled_AE
effects I-OSE_Labeled_AE
5 O
1 O
Central B-OSE_Labeled_AE
neurotoxicity I-OSE_Labeled_AE
26 O
5 O
Renal B-NonOSE_AE
Serum B-OSE_Labeled_AE
creatinine I-OSE_Labeled_AE
elevations I-OSE_Labeled_AE
6 O
10 O
Blood B-OSE_Labeled_AE
urea I-OSE_Labeled_AE
elevations I-OSE_Labeled_AE
17 O
22 O
Hepatic B-NonOSE_AE
Bilirubin B-OSE_Labeled_AE
elevations I-OSE_Labeled_AE
5 O
5 O
SGOT B-OSE_Labeled_AE
elevations I-OSE_Labeled_AE
20 O
19 O
Alkaline B-OSE_Labeled_AE
phosphatase I-OSE_Labeled_AE
elevations I-OSE_Labeled_AE
29 O
37 O
Electrolytes B-NonOSE_AE
loss I-NonOSE_AE
Sodium O
10 O
47 O
Potassium O
16 O
28 O
Calcium O
16 O
31 O
Magnesium O
61 O
43 O
Other B-NonOSE_AE
side I-NonOSE_AE
effects I-NonOSE_AE
Pain B-OSE_Labeled_AE
44 O
23 O
Asthenia B-OSE_Labeled_AE
41 O
11 O
Cardiovascular O
19 O
6 O
Respiratory O
10 O
6 O
Allergic B-OSE_Labeled_AE
11 O
2 O
Genitourinary O
10 O
2 O
Alopecia B-OSE_Labeled_AE
49 O
2 O
Mucositis B-OSE_Labeled_AE
8 O
1 O
In O
the O
narrative O
section O
that O
follows O
, O
the O
incidences O
of O
adverse O
events O
are O
based O
on O
data O
from O
1,893 O
patients O
with O
various O
types O
of O
tumors O
who O
received O
carboplatin O
as O
single O
agent O
therapy O
. O

Hematologic B-OSE_Labeled_AE
Toxicity I-OSE_Labeled_AE
Bone B-OSE_Labeled_AE
marrow I-OSE_Labeled_AE
suppression I-OSE_Labeled_AE
is O
the O
dose-limiting O
toxicity O
of O
carboplatin O
. O

Thrombocytopenia B-OSE_Labeled_AE
with O
platelet B-OSE_Labeled_AE
counts I-OSE_Labeled_AE
below I-OSE_Labeled_AE
5 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
, I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
mm I-OSE_Labeled_AE
3 I-OSE_Labeled_AE
occurs O
in O
25 O
% O
of O
the O
patients O
( O
35 O
% O
of O
pretreated O
ovarian B-Not_AE_Candidate
cancer I-Not_AE_Candidate
patients O
) O
; O
neutropenia B-OSE_Labeled_AE
with O
granulocyte B-OSE_Labeled_AE
counts I-OSE_Labeled_AE
below I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
, I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
mm I-OSE_Labeled_AE
3 I-OSE_Labeled_AE
occurs O
in O
16 O
% O
of O
the O
patients O
( O
21 O
% O
of O
pretreated O
ovarian B-Not_AE_Candidate
cancer I-Not_AE_Candidate
patients O
) O
; O
leukopenia B-OSE_Labeled_AE
with O
WBC B-OSE_Labeled_AE
counts I-OSE_Labeled_AE
below I-OSE_Labeled_AE
2 I-OSE_Labeled_AE
, I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
mm I-OSE_Labeled_AE
3 I-OSE_Labeled_AE
occurs O
in O
15 O
% O
of O
the O
patients O
( O
26 O
% O
of O
pretreated O
ovarian B-Not_AE_Candidate
cancer I-Not_AE_Candidate
patients O
) O
. O

The O
nadir O
usually O
occurs O
about O
day O
21 O
in O
patients O
receiving O
single O
agent O
therapy O
. O

By O
day O
28 O
, O
90 O
% O
of O
patients O
have O
platelet B-NonOSE_AE
counts I-NonOSE_AE
above I-NonOSE_AE
1 I-NonOSE_AE
0 I-NonOSE_AE
0 I-NonOSE_AE
, I-NonOSE_AE
0 I-NonOSE_AE
0 I-NonOSE_AE
0 I-NonOSE_AE
/ I-NonOSE_AE
mm I-NonOSE_AE
3 I-NonOSE_AE
; O
74 O
% O
have O
neutrophil B-NonOSE_AE
counts I-NonOSE_AE
above I-NonOSE_AE
2 I-NonOSE_AE
, I-NonOSE_AE
0 I-NonOSE_AE
0 I-NonOSE_AE
0 I-NonOSE_AE
/ I-NonOSE_AE
mm I-NonOSE_AE
3 I-NonOSE_AE
; O
67 O
% O
have O
leukocyte B-NonOSE_AE
counts I-NonOSE_AE
above I-NonOSE_AE
4 I-NonOSE_AE
, I-NonOSE_AE
0 I-NonOSE_AE
0 I-NonOSE_AE
0 I-NonOSE_AE
/ I-NonOSE_AE
mm I-NonOSE_AE
3 I-NonOSE_AE
. O

Marrow B-NonOSE_AE
suppression I-NonOSE_AE
is O
usually O
more O
severe O
in O
patients O
with O
impaired B-Not_AE_Candidate
kidney I-Not_AE_Candidate
function I-Not_AE_Candidate
. O

Patients O
with O
poor O
performance O
status O
have O
also O
experienced O
a O
higher O
incidence O
of O
severe O
leukopenia B-NonOSE_AE
and O
thrombocytopenia B-NonOSE_AE
. O

The O
hematologic B-OSE_Labeled_AE
effects I-OSE_Labeled_AE
, O
although O
usually O
reversible O
, O
have O
resulted O
in O
infectious B-OSE_Labeled_AE
or O
hemorrhagic O
complications I-OSE_Labeled_AE
in O
5 O
% O
of O
the O
patients O
treated O
with O
carboplatin O
, O
with O
drug O
related O
death B-NonOSE_AE
occurring O
in O
less O
than O
1 O
% O
of O
the O
patients O
. O

Fever B-OSE_Labeled_AE
has I-OSE_Labeled_AE
also I-OSE_Labeled_AE
been I-OSE_Labeled_AE
reported I-OSE_Labeled_AE
in I-OSE_Labeled_AE
patients I-OSE_Labeled_AE
with I-OSE_Labeled_AE
neutropenia I-OSE_Labeled_AE
. O

Anemia B-OSE_Labeled_AE
with O
hemoglobin B-OSE_Labeled_AE
less I-OSE_Labeled_AE
than I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
g I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
dL I-OSE_Labeled_AE
has O
been O
observed O
in O
71 O
% O
of O
the O
patients O
who O
started O
therapy O
with O
a O
baseline O
above O
that O
value O
. O

The O
incidence O
of O
anemia B-OSE_Labeled_AE
increases O
with O
increasing O
exposure O
to O
carboplatin O
. O

Transfusions O
have O
been O
administered O
to O
26 O
% O
of O
the O
patients O
treated O
with O
carboplatin O
( O
44 O
% O
of O
previously O
treated O
ovarian B-Not_AE_Candidate
cancer I-Not_AE_Candidate
patients O
) O
. O

Bone B-OSE_Labeled_AE
marrow I-OSE_Labeled_AE
depression I-OSE_Labeled_AE
may O
be O
more O
severe O
when O
carboplatin O
is O
combined O
with O
other O
bone B-NonOSE_AE
marrow I-NonOSE_AE
suppressing I-NonOSE_AE
drugs O
or O
with O
radiotherapy O
. O

Gastrointestinal B-OSE_Labeled_AE
Toxicity I-OSE_Labeled_AE
Vomiting B-OSE_Labeled_AE
occurs O
in O
65 O
% O
of O
the O
patients O
( O
81 O
% O
of O
previously O
treated O
ovarian B-Not_AE_Candidate
cancer I-Not_AE_Candidate
patients O
) O
and O
in O
about O
one-third O
of O
these O
patients O
it O
is O
severe O
. O

Carboplatin O
, O
as O
a O
single O
agent O
or O
in O
combination O
, O
is O
significantly O
less O
emetogenic B-OSE_Labeled_AE
than O
cisplatin O
; O
however O
, O
patients O
previously O
treated O
with O
emetogenic B-NonOSE_AE
agents I-NonOSE_AE
, O
especially O
cisplatin O
, O
appear O
to O
be O
more O
prone O
to O
vomiting B-NonOSE_AE
. O

Nausea B-OSE_Labeled_AE
alone O
occurs O
in O
an O
additional O
10 O
% O
to O
15 O
% O
of O
patients O
. O

Both O
nausea B-OSE_Labeled_AE
and O
vomiting B-OSE_Labeled_AE
usually O
cease O
within O
24 O
hours O
of O
treatment O
and O
are O
often O
responsive O
to O
antiemetic O
measures O
. O

Although O
no O
conclusive O
efficacy O
data O
exist O
with O
the O
following O
schedules O
, O
prolonged O
administration O
of O
carboplatin O
, O
either O
by O
continuous O
24-hour O
infusion O
or O
by O
daily O
pulse O
doses O
given O
for O
5 O
consecutive O
days O
, O
was O
associated O
with O
less O
severe O
vomiting B-OSE_Labeled_AE
than O
the O
single-dose O
intermittent O
schedule O
. O

Emesis B-NonOSE_AE
was O
increased O
when O
carboplatin O
was O
used O
in O
combination O
with O
other O
emetogenic O
compounds O
. O

Other O
gastrointestinal B-OSE_Labeled_AE
effects O
observed O
frequently O
were O
pain I-OSE_Labeled_AE
, O
in O
17 O
% O
of O
the O
patients O
; O
diarrhea B-OSE_Labeled_AE
, O
in O
6 O
% O
; O
and O
constipation B-OSE_Labeled_AE
, O
also O
in O
6 O
% O
. O

Neurologic B-OSE_Labeled_AE
Toxicity I-OSE_Labeled_AE
Peripheral B-OSE_Labeled_AE
neuropathies I-OSE_Labeled_AE
have O
been O
observed O
in O
4 O
% O
of O
the O
patients O
receiving O
carboplatin O
( O
6 O
% O
of O
pretreated O
ovarian B-Not_AE_Candidate
cancer I-Not_AE_Candidate
patients O
) O
with O
mild O
paresthesias B-OSE_Labeled_AE
occurring O
most O
frequently O
. O

Carboplatin O
therapy O
produces O
significantly O
fewer O
and O
less O
severe O
neurologic B-OSE_Labeled_AE
side I-OSE_Labeled_AE
effects I-OSE_Labeled_AE
than O
does O
therapy O
with O
cisplatin O
. O

However O
, O
patients O
older O
than O
65 O
years O
and/or O
previously O
treated O
with O
cisplatin O
appear O
to O
have O
an O
increased O
risk O
( O
10 O
% O
) O
for O
peripheral B-OSE_Labeled_AE
neuropathies I-OSE_Labeled_AE
. O

In O
70 O
% O
of O
the O
patients O
with O
pre-existing O
cisplatin-induced O
peripheral B-Not_AE_Candidate
neurotoxicity I-Not_AE_Candidate
, O
there O
was O
no O
worsening O
of O
symptoms O
during O
therapy O
with O
carboplatin O
. O

Clinical O
ototoxicity B-OSE_Labeled_AE
and O
other O
sensory B-OSE_Labeled_AE
abnormalities I-OSE_Labeled_AE
such O
as O
visual B-OSE_Labeled_AE
disturbances I-OSE_Labeled_AE
and O
change B-OSE_Labeled_AE
in I-OSE_Labeled_AE
taste I-OSE_Labeled_AE
have O
been O
reported O
in O
only O
1 O
% O
of O
the O
patients O
. O

Central B-OSE_Labeled_AE
nervous I-OSE_Labeled_AE
system I-OSE_Labeled_AE
symptoms I-OSE_Labeled_AE
have O
been O
reported O
in O
5 O
% O
of O
the O
patients O
and O
appear O
to O
be O
most O
often O
related O
to O
the O
use O
of O
antiemetics O
. O

Although O
the O
overall O
incidence O
of O
peripheral B-OSE_Labeled_AE
neurologic I-OSE_Labeled_AE
side I-OSE_Labeled_AE
effects I-OSE_Labeled_AE
induced O
by O
carboplatin O
is O
low O
, O
prolonged O
treatment O
, O
particularly O
in O
cisplatin O
pretreated O
patients O
, O
may O
result O
in O
cumulative O
neurotoxicity B-OSE_Labeled_AE
. O

Nephrotoxicity B-OSE_Labeled_AE
Development O
of O
abnormal B-OSE_Labeled_AE
renal I-OSE_Labeled_AE
function I-OSE_Labeled_AE
test I-OSE_Labeled_AE
results O
is O
uncommon O
, O
despite O
the O
fact O
that O
carboplatin O
, O
unlike O
cisplatin O
, O
has O
usually O
been O
administered O
without O
high-volume O
fluid O
hydration O
and/or O
forced O
diuresis B-NonOSE_AE
. O

The O
incidences O
of O
abnormal B-OSE_Labeled_AE
renal I-OSE_Labeled_AE
function I-OSE_Labeled_AE
tests I-OSE_Labeled_AE
reported O
are O
6 O
% O
for O
serum O
creatinine O
and O
14 O
% O
for O
blood O
urea O
nitrogen O
( O
10 O
% O
and O
22 O
% O
, O
respectively O
, O
in O
pretreated O
ovarian B-Not_AE_Candidate
cancer I-Not_AE_Candidate
patients O
) O
. O

Most O
of O
these O
reported O
abnormalities O
have O
been O
mild O
and O
about O
one-half O
of O
them O
were O
reversible O
. O

Creatinine O
clearance O
has O
proven O
to O
be O
the O
most O
sensitive O
measure O
of O
kidney O
function O
in O
patients O
receiving O
carboplatin O
, O
and O
it O
appears O
to O
be O
the O
most O
useful O
test O
for O
correlating O
drug O
clearance O
and O
bone B-NonOSE_AE
marrow I-NonOSE_AE
suppression I-NonOSE_AE
. O

Twenty-seven O
percent O
of O
the O
patients O
who O
had O
a O
baseline O
value O
of O
60 O
mL/min O
or O
more O
demonstrated O
a O
reduction O
below O
this O
value O
during O
carboplatin O
therapy O
. O

Hepatic B-OSE_Labeled_AE
Toxicity I-OSE_Labeled_AE
The O
incidences O
of O
abnormal B-OSE_Labeled_AE
liver I-OSE_Labeled_AE
function I-OSE_Labeled_AE
tests I-OSE_Labeled_AE
in O
patients O
with O
normal O
baseline O
values O
were O
reported O
as O
follows O
: O
total O
bilirubin O
, O
5 O
% O
; O
SGOT O
, O
15 O
% O
; O
and O
alkaline O
phosphatase O
, O
24 O
% O
; O
( O
5 O
% O
, O
19 O
% O
, O
and O
37 O
% O
, O
respectively O
, O
in O
pretreated O
ovarian B-Not_AE_Candidate
cancer I-Not_AE_Candidate
patients O
) O
. O

These O
abnormalities O
have O
generally O
been O
mild O
and O
reversible O
in O
about O
one-half O
of O
the O
cases O
, O
although O
the O
role O
of O
metastatic B-Not_AE_Candidate
tumor I-Not_AE_Candidate
in I-Not_AE_Candidate
the I-Not_AE_Candidate
liver I-Not_AE_Candidate
may O
complicate O
the O
assessment O
in O
many O
patients O
. O

In O
a O
limited O
series O
of O
patients O
receiving O
very O
high O
dosages O
of O
carboplatin O
and O
autologous B-Not_AE_Candidate
bone I-Not_AE_Candidate
marrow I-Not_AE_Candidate
transplantation I-Not_AE_Candidate
, O
severe O
abnormalities B-OSE_Labeled_AE
of I-OSE_Labeled_AE
liver I-OSE_Labeled_AE
function I-OSE_Labeled_AE
tests I-OSE_Labeled_AE
were O
reported O
. O

Electrolyte B-OSE_Labeled_AE
Changes I-OSE_Labeled_AE
The O
incidences O
of O
abnormally O
decreased B-OSE_Labeled_AE
serum I-OSE_Labeled_AE
electrolyte I-OSE_Labeled_AE
values I-OSE_Labeled_AE
reported O
were O
as O
follows O
: O
sodium O
, O
29 O
% O
; O
potassium O
, O
20 O
% O
; O
calcium O
, O
22 O
% O
; O
and O
magnesium O
, O
29 O
% O
; O
( O
47 O
% O
, O
28 O
% O
, O
31 O
% O
, O
and O
43 O
% O
, O
respectively O
, O
in O
pretreated O
ovarian B-Not_AE_Candidate
cancer I-Not_AE_Candidate
patients O
) O
. O

Electrolyte O
supplementation O
was O
not O
routinely O
administered O
concomitantly O
with O
carboplatin O
, O
and O
these O
electrolyte B-OSE_Labeled_AE
abnormalities I-OSE_Labeled_AE
were O
rarely O
associated O
with O
symptoms O
. O

Allergic O
Reactions O
Hypersensitivity B-OSE_Labeled_AE
to O
carboplatin O
has O
been O
reported O
in O
2 O
% O
of O
the O
patients O
. O

These O
allergic B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
have O
been O
similar O
in O
nature O
and O
severity O
to O
those O
reported O
with O
other O
platinum-containing O
compounds O
, O
i.e. O
, O
rash B-OSE_Labeled_AE
, O
urticaria B-OSE_Labeled_AE
, O
erythema B-OSE_Labeled_AE
, O
pruritus B-OSE_Labeled_AE
, O
and O
rarely O
bronchospasm B-OSE_Labeled_AE
and O
hypotension B-OSE_Labeled_AE
. O

Anaphylactic B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
have O
been O
reported O
as O
part O
of O
postmarketing O
surveillance O
( O
see O
WARNINGS O
) O
. O

These O
reactions O
have O
been O
successfully O
managed O
with O
standard O
epinephrine O
, O
corticosteroid O
, O
and O
antihistamine O
therapy O
. O

Injection O
Site O
Reactions O
Injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
, O
including O
redness O
, O
swelling O
, O
and O
pain O
, O
have O
been O
reported O
during O
postmarketing O
surveillance O
. O

Necrosis B-OSE_Labeled_AE
associated I-OSE_Labeled_AE
with I-OSE_Labeled_AE
extravasation I-OSE_Labeled_AE
has O
also O
been O
reported O
. O

Other O
Events O
Pain B-OSE_Labeled_AE
and O
asthenia B-OSE_Labeled_AE
were O
the O
most O
frequently O
reported O
miscellaneous O
adverse O
effects O
; O
their O
relationship O
to O
the O
tumor B-NonOSE_AE
and O
to O
anemia B-NonOSE_AE
was O
likely O
. O

Alopecia B-OSE_Labeled_AE
was O
reported O
( O
3 O
% O
) O
. O

Cardiovascular B-OSE_Labeled_AE
, O
respiratory O
, O
genitourinary O
, O
and O
mucosal O
side I-OSE_Labeled_AE
effects I-OSE_Labeled_AE
have O
occurred O
in O
6 O
% O
or O
less O
of O
the O
patients O
. O

Cardiovascular B-OSE_Labeled_AE
events I-OSE_Labeled_AE
( O
cardiac B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
embolism B-OSE_Labeled_AE
, O
cerebrovascular B-OSE_Labeled_AE
accidents I-OSE_Labeled_AE
) O
were O
fatal B-NonOSE_AE
in O
less O
than O
1 O
% O
of O
the O
patients O
and O
did O
not O
appear O
to O
be O
related O
to O
chemotherapy O
. O

Cancer B-Not_AE_Candidate
-associated O
hemolytic B-Not_AE_Candidate
uremic I-Not_AE_Candidate
syndrome I-Not_AE_Candidate
has O
been O
reported O
rarely O
. O

Malaise B-OSE_Labeled_AE
, O
anorexia B-OSE_Labeled_AE
, O
hypertension B-OSE_Labeled_AE
, O
dehydration B-OSE_Labeled_AE
, O
and O
stomatitis B-OSE_Labeled_AE
have O
been O
reported O
as O
part O
of O
postmarketing O
surveillance O
. O

